Related Experiment Video
Updated: Dec 29, 2025

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
PET Imaging of Prostate Cancer Using Radiolabeled Choline
Mohsen Beheshti1, Werner Langsteger
1Department of Nuclear Medicine & Endocrinology, PET-CT Center Linz, St. Vincent's Hospital, Seilerstaette 4, A-4020 Linz, Austria.
Abstract:
Although PET using fludeoxyglucose F 18 (FDG) is a promising modality for metabolic imaging of different tumors, the results in prostate cancer have been somewhat inconsistent. Low FDG avidity of most prostate cancer cells and urinary activity are suggested as the main limitations of FDG PET for the evaluation of prostate cancer. Prostate cancer exhibits increased choline metabolism, which is the rationale for using radiolabeled choline for PET. This article describes the basic concepts of radiolabeled choline regarding pharmacokinetics, radiation dosimetry, synthesis, and biodistribution, in addition to advances concerning clinical PET using 11C- and 18F-choline in primary staging and restaging of prostate cancer patients.
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

